Pemvidutide Guide
Altimmune
Complete guide to Pemvidutide (ALT-801 / AZD9550) — Altimmune
What Is Pemvidutide?
Pemvidutide (development names ALT-801 and AZD9550) is being developed by Altimmune in partnership with AstraZeneca. It is a balanced dual agonist of the GLP-1 receptor and the glucagon receptor (GCGR), administered as a once-weekly subcutaneous injection.
The GLP-1 component suppresses appetite and slows gastric emptying — the same mechanism as semaglutide (Ozempic/Wegovy). The glucagon component adds a distinct thermogenic effect: it increases metabolic rate, enhances fat oxidation, and promotes fat clearance from the liver. Together, these two pathways produce weight loss that is both significant and qualitatively different from pure GLP-1 monotherapy.
Why it matters: The glucagon component drives fat loss preferentially, which is why DEXA scan data from MOMENTUM showed pemvidutide users retaining lean muscle mass at rates superior to semaglutide. For patients focused on body composition — not just the number on the scale — this distinction is critical.
MOMENTUM Phase 2b Trial Results
Weight Loss (1.2mg, 24 wks)
10.7%
Participants on the 1.2mg weekly dose lost an average of 10.7% of body weight at 24 weeks. Higher doses demonstrated up to 15.6% weight loss, consiste
Lean Mass Retention vs Semaglutide
Superior
Weight Loss (Higher Dose)
15.6%
Participants on the 1.2mg weekly dose lost an average of 10.7% of body weight at 24 weeks. Higher doses demonstrated up to 15.6% weight loss, consiste
The Dual Mechanism: GLP-1 + Glucagon
GLP-1 Receptor Agonism
Suppresses appetite centrally and peripherally. Slows gastric emptying — prolongs satiety. Improves glucose-stimulated insulin secretion. Reduces fasting and postprandial glucose. Proven cardiovascula
Glucagon Receptor (GCGR) Agonism
Increases basal metabolic rate (thermogenic effect). Enhances fat oxidation — burns fat preferentially. Promotes hepatic fat clearance (MASH potential). Improves lipid profiles (LDL, triglycerides). S
Why the Combination Outperforms Either Alone
GLP-1 alone reduces calories in. Glucagon receptor activation increases calories out by raising metabolic rate. Together, pemvidutide attacks obesity from both ends of the energy balance equation — wh
Muscle Preservation: Why Pemvidutide Is Different
DEXA
Objective body composition scans in MOMENTUM — not just scale weight
Fat-First
GCGR activation preferentially mobilizes adipose fat stores over muscle protein
Better
Superior lean mass retention vs semaglutide at matched weight loss
MASH / Liver Disease Potential
Beyond weight loss and muscle preservation, pemvidutide is being studied for MASH (metabolic dysfunction-associated steatohepatitis) — formerly called NASH. This is the progressive form of fatty liver disease that can advance to cirrhosis and liver failure.
The glucagon receptor plays a well-established role in hepatic (liver) fat metabolism. GCGR activation directly reduces liver fat accumulation by promoting fat oxidation in hepatocytes and reducing fat synthesis. This same mechanism that spares muscle also clears fat from the liver.
Other GLP-1/glucagon dual agonists like Survodutide have shown remarkable MASH results (83% resolution in Phase 2). Pemvidutide's similar mechanism positions it as a credible candidate for liver disease treatment — though liver-specific Phase 2/3 data is still maturing.
Development Timeline & ADVANCE Phase 3
2023:
AstraZeneca licenses pemvidutide from Altimmune (ALT-801 becomes AZD9550)
2024:
MOMENTUM Phase 2b results published, DEXA muscle data released
2025–2026:
Phase 3 ADVANCE trial launches — obesity indication, longer duration
2027–2028:
Expected Phase 3 completion and potential FDA submission
2028+:
Potential FDA approval (obesity and/or MASH)
Vital Protocol FAQs
Will pemvidutide raise my blood sugar like regular glucagon?
No. In isolated form, glucagon raises blood sugar — but pemvidutide's GLP-1 component strongly counteracts this by enhancing insulin secretion. MOMENTUM trial data showed no clinically meaningful bloo
How does pemvidutide's weight loss compare to Zepbound or Wegovy?
At 24 weeks, pemvidutide's 10.7–15.6% weight loss is broadly comparable to semaglutide at similar timepoints. However, direct comparisons are difficult because different trials use different time hori
When will pemvidutide be available?
Pemvidutide is expected to enter Phase 3 ADVANCE trials in 2025–2026. If Phase 3 succeeds, FDA submission could occur in 2027–2028, with potential approval to follow. AstraZeneca's backing provides th
Guide FAQs
Complete guide to Pemvidutide (ALT-801 / AZD9550) — Altimmune
Yes. Shotlee supports tracking Pemvidutide doses, side effects, and health metrics. It is free to use.
PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Pemvidutide research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.
Before starting Pemvidutide, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.
Evidence-based lifestyle modifications that complement Pemvidutide protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Pemvidutide data in Shotlee to identify which combinations drive your best results.
References
Track Your Pemvidutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free